Press release
Graves Disease Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Statistics, Revenue, Prevalence, and Companies by DelveInsight
Graves Disease Drugs Market
(Albany, USA) DelveInsight's "Graves' Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Graves' Disease, historical and forecasted epidemiology as well as the Graves' Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Graves' Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Graves' Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
The Graves' Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Graves' Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Graves' Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Graves' Disease market.
Unlock detailed insights into the Graves' Disease Market by downloading the comprehensive report from DelveInsight @ Graves' Disease Treatment Market Size [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Key Takeaways from the Graves' Disease Market Report
* In May 2025, Immunovant Sciences GmbH announced results of a Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Patients With Graves' Disease
* In May 2025, Biohaven Pharmaceuticals, Inc announced results of an Open-Label Biomarker Study of BHV-1300 in Graves' Disease
* In January 2025, Sling Therapeutics, Inc., a late-stage biopharmaceutical company developing an oral small molecule therapy for thyroid eye disease, announced topline results on the efficacy and safety of linsitinib from the Phase IIb/III LIDS trial in patients with active, moderate to severe TED.
* In September 2024:- Immunovant Sciences GmbH- A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED). To evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.
* In September 2024:- Amgen- The study consists of a randomized double-masked, placebo-controlled, parallel-group, multicenter trial with an optional open-label treatment period for proptosis non-responders who complete the Double-masked Treatment Period. The main objective of the study is to evaluate the effect of teprotumumab subcutaneous administration versus placebo on the proptosis responder rate (ie, the percentage of participants with a greater than or equal to 2-mm reduction from Baseline in the study eye without deterioration [ greater than or equal to 2-mm increase] of proptosis in the fellow eye) at Week 24.
* As per DelveInsight's estimates, Graves' disease is the primary cause of hyperthyroidism, responsible for 60-80% of cases. Despite this prevalence, it is relatively uncommon, impacting roughly 1.2% of the US population.
* According to American Thyroid Association (2024), more than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease. Women are five to eight times more likely than men to have thyroid problems.
* As per data from the National Institute of Diabetes and Digestive and Kidney Diseases (2021), Graves' disease affects nearly 1 in 100 Americans.
* According to Shang et al. (2024), an estimated 2.7-3.0% of the adult Chinese population-over 31 million individuals-are affected by one or more autoimmune diseases, a prevalence comparable to that seen in Western populations. The predominant contributors to this burden are autoimmune thyroid diseases and rheumatoid arthritis.
* The leading Graves' Disease Companies such as Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals, AV7 Limited, Medtronic, Pfizer, Sanguine Biosciences, Tourmaline Bio Inc., Horizon Pharma USA Inc., Viridian Therapeutics Inc., Innovent Biologics Co. Ltd, Hoffmann-La Roche and others.
* Promising Graves' Disease Therapies such as linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
Gain a competitive edge in the Graves' Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Graves' Disease Treatment Drugs [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Graves' Disease Epidemiology Segmentation in the 7MM
* Graves' Disease Gender-specific Cases
* Total Graves' Disease Prevalent Cases
* Graves' Disease Age Group-specific Cases
* Total Graves' Disease Treated Cases
Graves' Disease Market Insights
Graves' disease, an autoimmune disorder and the leading cause of hyperthyroidism, characterized by symptoms such as weight loss, rapid heartbeat, and in some cases, thyroid eye disease. While traditional treatments like anti-thyroid medications, radioactive iodine therapy, and thyroidectomy remain the cornerstone of management. Anti-thyroid drugs, such as methimazole and propylthiouracil (PTU), are commonly used to suppress thyroid hormone production, with Methimazole being the preferred first-line therapy due to its efficacy and safety profile. Radioactive iodine therapy is favored in the United States, especially when drug therapy is ineffective or contraindicated. It induces hypothyroidism, requiring thyroid hormone replacement. However, it is not recommended for patients with Graves' ophthalmopathy or smokers due to potential risks.
Discover key developments and opportunities in the Graves' Disease Market. Click here to learn more from DelveInsight's latest report @ Graves' Disease Market Size [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Graves' Disease Treatment Market
The DelveInsight's Graves' Disease treatment market report gives a thorough understanding of Graves' Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. The Graves' Disease treatment market has experienced significant growth and evolution in recent years, reflecting the increasing prevalence of Graves' disease, an autoimmune disorder that affects the thyroid gland. The Graves' Disease treatment market has witnessed the advent of innovative treatment modalities, including anti-thyroid drugs, radioactive iodine therapy, and surgery
Graves' Disease Companies and Therapies
* Sling Therapeutics, Inc.: linsitinib
* Immunovant Sciences GmbH: Batoclimab
* Amgen: Teprotumumab
* Viridian Therapeutics Inc.:- VRDN-001 10 mg/kg
* Hoffmann-La Roche: Satralizumab
Download DelveInsight's Graves' Disease Market report today and stay ahead in this rapidly evolving field. @ Graves' Disease Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Scope of the Graves' Disease Market Report
* Coverage- 7MM
* Graves' Disease Companies- Apitope International NV, Quintiles Inc., European Commission, Immunovant Sciences GmbH, Novartis Pharmaceuticals (SWX: NOVN), AV7 Limited, Medtronic (NYSE: MDT), Pfizer (NYSE: PFE), Sanguine Biosciences, Tourmaline Bio Inc. (NASDAQ: TRML), Horizon Pharma USA Inc., Viridian Therapeutics Inc. (NASDAQ: VRDN), Innovent Biologics Co. Ltd (HKEX: 1801), Hoffmann-La Roche (SWX: RO), and others.
* Graves' Disease Therapies- linsitinib, Batoclimab, Teprotumumab, VRDN-001 10 mg/kg, Satralizumab, IBI311, and others.
* Graves' Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
* Graves' Disease Unmet Needs, KOL's views, Analyst's views, Graves' Disease Market Access and Reimbursement
Download the report to understand which factors are driving Graves' Disease Market Dynamics @ Graves' Disease Market Trends [https://www.delveinsight.com/sample-request/graves-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Table of Content
1. Key Insights
2. Graves' Disease Executive Summary
3. Competitive Intelligence Analysis for Graves' Disease
4. Graves' Disease: Market Overview at a Glance
5. Graves' Disease: Disease Background and Overview
6. Patient Journey
7. Graves' Disease Epidemiology and Patient Population
8. Graves' Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Graves' Disease Unmet Needs
10. Key Endpoints of Graves' Disease Treatment
11. Graves' Disease Marketed Products
12. Graves' Disease Emerging Therapies
13. Graves' Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Graves' Disease Market Outlook
16. Graves' Disease Market Access and Reimbursement Overview
17. Graves' Disease KOL Views
18. Graves' Disease Market Drivers
19. Graves' Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graves-disease-drugs-market-2034-clinical-trials-ema-pdma-fda-approvals-medication-therapies-statistics-revenue-prevalence-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Graves Disease Drugs Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, Statistics, Revenue, Prevalence, and Companies by DelveInsight here
News-ID: 4054246 • Views: …
More Releases from ABNewswire
EleganceBrew Reports Record Holiday Sales Growth as Health-Conscious Consumers C …
EleganceBrew celebrates unprecedented holiday season success with triple-digit growth in wellness tea and premium coffee sales. The company attributes its performance to increasing consumer preference for gifts that combine luxury with health benefits, particularly among millennials and Gen Z shoppers.
As the holiday shopping season reaches its peak, EleganceBrew is thrilled to announce exceptional sales performance that has exceeded all projections, with particular strength in its wellness-focused product lines and curated…
From Heritage to Modern Elegance: Chow Sang Sang Redefines Meaningful Jewellery
Image: https://www.abnewswire.com/upload/2025/12/2ef0a71ce13c92816c1d174f1f64452a.jpg
Jewellery is more than a fashion statement-it is an emotional expression, a mark of identity, and a cherished symbol of life's most meaningful occasions. Whether you're celebrating love, honouring tradition, or elevating everyday elegance, choosing the right jewellery matters. This is where Chow Sang Sang shines as a brand [https://tracking.icubeswire.co/aff_c?offer_id=5781&aff_id=11853&url_id=11656] that consistently delivers excellence, making it the best choice every time you shop for fine jewellery.
With a legacy spanning…
Tieks Honors the Success of Its Pink Ribbon Campaign and Introduces the Holiday …
Image: https://www.abnewswire.com/upload/2025/12/a196054eb455ee2812f6daa4ed65cf87.jpg
LOS ANGELES - Tieks, the Los Angeles based luxury ballet flat maker, celebrates the success of its Pink Ribbon campaign and presents the Holiday Gift Calendar 2025. The calendar is created to share the spirit of giving through design, craftsmanship, and care.
Pink Ribbon Tieks [https://tieks.com/pink-ribbon-ballet-flats] is Tieks' first-ever embellished style featuring a symbolic leather bow on the iconic Ballerina Pink Tieks. This limited-edition honors Breast Cancer Awareness Month by…
OSpark.ai Launches as a Free All-Round AI Assistant Merging Smart Tools, Creativ …
San Francisco - OctoPaul [https://octopaul.com/] today announced the launch of OSpark.ai [https://ospark.ai/?utm_source=tobeseen&utm_medium=geo&utm_campaign=v10] - the free all-round AI assistant that combines smart searches, web/doc summarization, and image recognition with AI-driven image generation and podcast creation, all while giving unlimited access to top-tier LLMs. It's like having a 24/7 sidekick that simplifies work, play, and daily tasks with seamless AI magic - no subscriptions, no hidden fees, just pure convenience.
Image: https://www.abnewswire.com/upload/2025/12/5041a6803bc9d15e014bce9659717adc.jpg
Whether a…
More Releases for Graves
Graves' Disease Market New Product Development & Latest Trends
Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overproduction of thyroid hormones, through antibodies that stimulate the thyroid gland. It is among the most common thyroid-related autoimmune conditions, disproportionately affecting women between 30-60 years of age. Beyond metabolic complications such as weight loss, heat intolerance, and palpitations, Graves' disease can cause thyroid eye disease (TED), which impairs vision and quality of life.
For decades, treatment has relied on antithyroid…
Graves Ophthalmopathy Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Graves Ophthalmopathy Pipeline Insight 2024" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Graves Ophthalmopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Graves Ophthalmopathy Research. Learn more about…
Search for graves and burials in Minsk
If you are looking for information about the location of the grave in Minsk or other regions of Belarus, the company https://verimby.com +375293887408 (Viber); +375447498518 (WhatsApp) offers professional assistance in this important matter. We specialize in finding burial sites, providing detailed data and providing support in restoring lost ties with the past, creating a family tree, even if you are in another country.
Why can the search for graves in Belarus…
Graves' Disease Treatment Market Size, Drugs, Companies 2034 | DelveInsight
Graves' Disease Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Graves' Disease Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Graves' Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Graves' Disease, historical and…
Japan Graves' disease Market Size & Growth Analysis Report, 2019-2025
Japan Graves' disease market is growing at a CAGR of around 4.7% during the forecast period. According to the WHO, around 10.1% of the country's population is suffering from diabetes, among which, the individuals suffering from type-1 diabetes are more prone to develop Grave's disease in the near future. According to IDF, around 2.2 per thousand children and adolescents aged 14 years and below are suffering from type-1 diabetes in…
Global Graves Disease Market Status and Outlook (2020-2025)
Global Info Research offers a latest published report on Graves Disease Analysis and Forecast 2020-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Graves Disease Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure and tables:
https://www.globalinforesearch.com/reports/515950/graves-disease
Market…
